4basebio (4BB) Competitors GBX 989 +19.00 (+1.96%) As of 08/1/2025 10:05 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock 4BB vs. SLN, PRTC, OXB, HZD, FARN, VRP, ARIX, AVCT, BVXP, and CIRShould you be buying 4basebio stock or one of its competitors? The main competitors of 4basebio include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Avacta Group (AVCT), Bioventix (BVXP), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry. 4basebio vs. Its Competitors Silence Therapeutics PureTech Health Oxford Biomedica Horizon Discovery Group plc (HZD.L) Faron Pharmaceuticals Oy Verona Pharma plc (VRP.L) Arix Bioscience Avacta Group Bioventix Circassia Group Silence Therapeutics (LON:SLN) and 4basebio (LON:4BB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership. Is SLN or 4BB more profitable? Silence Therapeutics' return on equity of 0.00% beat 4basebio's return on equity.Company Net Margins Return on Equity Return on Assets Silence TherapeuticsN/A N/A N/A 4basebio N/A -231.29%-54.30% Which has higher valuation & earnings, SLN or 4BB? Silence Therapeutics has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics£11.35M0.00N/A-£48.60N/A4basebio£311K407.37-£9.84M-£0.78-1,267.95 Does the media refer more to SLN or 4BB? In the previous week, 4basebio's average media sentiment score of 0.67 beat Silence Therapeutics' score of 0.00 indicating that 4basebio is being referred to more favorably in the news media. Company Overall Sentiment Silence Therapeutics Neutral 4basebio Positive Do analysts prefer SLN or 4BB? 4basebio has a consensus price target of GBX 1,600, indicating a potential upside of 61.78%. Given 4basebio's stronger consensus rating and higher probable upside, analysts plainly believe 4basebio is more favorable than Silence Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.004basebio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in SLN or 4BB? 2.0% of 4basebio shares are owned by institutional investors. 68.4% of 4basebio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Summary4basebio beats Silence Therapeutics on 7 of the 11 factors compared between the two stocks. Get 4basebio News Delivered to You Automatically Sign up to receive the latest news and ratings for 4BB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding 4BB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart 4BB vs. The Competition Export to ExcelMetric4basebioBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£126.69M£134.51M£5.49B£3.03BDividend YieldN/A3.74%4.73%5.02%P/E Ratio-1,267.953.8128.78176.75Price / Sales407.374,246.60372.20264,362.45Price / Cash16.0813.1935.4527.97Price / Book-24.1239.388.274.53Net Income-£9.84M-£90.99M£3.25B£5.90B7 Day Performance5.10%-1.84%-3.70%12.58%1 Month Performance2.22%11.20%4.34%6.10%1 Year Performance-29.36%189.79%25.90%71.60% 4basebio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)4BB4basebio1.8231 of 5 starsGBX 989+2.0%GBX 1,600+61.8%-34.1%£126.69M£311K-1,267.95101News CoverageSLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100Positive NewsHigh Trading VolumePRTCPureTech Health2.548 of 5 starsGBX 142.80+2.7%GBX 455+218.6%-18.6%£428.94M£521.32K-5.86300News CoverageOXBOxford Biomedica1.1355 of 5 starsGBX 389.53+1.7%GBX 390+0.1%+24.9%£414.08M£98.31M-2.89891News CoverageHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416FARNFaron Pharmaceuticals OyN/AGBX 201+1.8%N/A+17.2%£269.85MN/A-5.3834News CoverageVRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919AVCTAvacta GroupN/AGBX 40.50+15.9%N/A-27.7%£153.86M£26.29M-5.21120News CoveragePositive NewsHigh Trading VolumeBVXPBioventixN/AGBX 2,750flatN/A-41.5%£144.00M£13.65M17.7912CIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down Related Companies and Tools Related Companies Silence Therapeutics Competitors PureTech Health Competitors Oxford Biomedica Competitors Horizon Discovery Group plc (HZD.L) Competitors Faron Pharmaceuticals Oy Competitors Verona Pharma plc (VRP.L) Competitors Arix Bioscience Competitors Avacta Group Competitors Bioventix Competitors Circassia Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:4BB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4basebio PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share 4basebio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free 4BB Stock Alerts